MACE (Major Adverse Cardiovascular Events)
The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.
Definition
A composite endpoint used in cardiovascular outcomes trials, typically defined as cardiovascular death + nonfatal myocardial infarction + nonfatal stroke. GLP-1 cardiovascular trials report MACE as the primary endpoint: SELECT (semaglutide in obesity) showed 20% relative risk reduction, SUSTAIN-6 (semaglutide T2D) 26%, LEADER (liraglutide) 13%. Effect size correlates roughly with weight loss but extends beyond what weight reduction alone explains.
Top GLP-1 cardiovascular studies →
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Major trials
Looking for more depth?
- Top GLP-1 cardiovascular studies
- Browse the full GLP-1 glossary (61 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers